Barnes Q2: Topline Miss, Maintained 2023 EPS Forecast & More

Barnes Group Inc (NYSE: B) reported 

Barnes Group Inc (NYSE:B) reported second-quarter FY23 sales growth of 5.5% year-over-year at $338.98 million, +5% on an organic basis, missing the consensus of $339.166 million.

Adjusted EPS of $0.58 (+4% Y/Y) beat the consensus of $0.54.

Operating income was $26.01 million, compared to a loss of $(28.18) million a year ago, and the margin was 7.7%.

Adjusted operating margin expanded by 30 bps to 12.8%, with income of $43.5 million (+8% Y/Y).

Barnes’ operating cash flow for six months ended June 30, 2023, totaled $42.5 million, compared to $8.52 million a year ago. Free cash flow was $20.85 million.

Industrial segment sales increased by 2% Y/Y to $217 million, and Aerospace segment sales increased by 12% Y/Y to $122 million.

Aerospace OEM backlog was at $805 million, up 7% Y/Y. The company expects to convert ~50% of this backlog to revenue over the next 12 months.

At the end of the quarter, the company’s liquidity comprised $75 million in cash and $537 million available under the revolving credit facility.

FY23 Outlook: Barnes boosts organic sales growth forecast to 7%-9% (prior view 6%-8%). The company continues to see adjusted operating margin of 12.5%-13.5%.

B continues to expect adjusted EPS of $2.15-$2.30 versus the consensus of $2.25.

Price Action: B shares traded lower by 5.67% at $40.01 on the last check Friday.

Total
0
Shares
Related Posts
Read More

NRx Pharmaceuticals Publishes Shareholder Update Letter; Update Highlights Potential Implications Of The Company’s Recent Activities At The Annual Meeting Of The American Society Of Clinical Psychopharmacology

The June 2024 meeting of the American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intravenous ketamine and intranasal S-ketamine as the emerging standard of care for treating

NRXP